Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-07-08
2008-07-08
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S467000
Reexamination Certificate
active
07396857
ABSTRACT:
Therapeutic combinations useful in the treatment or prevention of depression or other mood disorders, to pharmaceutical compositions containing said combinations, and to their use in the treatment or prophylaxis of depression or other mood disorders are provided. Such compounds are of formula I:or a pharmaceutically acceptable salt thereof, wherein each of R1, R2, R3, n, y, and Ar are as defined and described herein.
REFERENCES:
patent: 3513239 (1970-05-01), Wiley
patent: 3759927 (1973-09-01), Huebner
patent: 4617314 (1986-10-01), Tahara et al.
patent: 5756532 (1998-05-01), Stack et al.
patent: 6150402 (2000-11-01), Wechter et al.
patent: 6274171 (2001-08-01), Sherman et al.
patent: 6403120 (2002-06-01), Sherman et al.
patent: 6419958 (2002-07-01), Sherman et al.
patent: 6444708 (2002-09-01), Rudolph et al.
patent: 6638972 (2003-10-01), Kelly et al.
patent: 6667322 (2003-12-01), Gross et al.
patent: 6706757 (2004-03-01), Greenblatt et al.
patent: 6969730 (2005-11-01), Cowart et al.
patent: 7045545 (2006-05-01), Briner et al.
patent: 7208502 (2007-04-01), Solow-Cordero et al.
patent: 2003/0092770 (2003-05-01), Sholnick
patent: 2003/0134835 (2003-07-01), Hancock et al.
patent: 2004/0029972 (2004-02-01), Howard, Jr.
patent: 2005/0124692 (2005-06-01), Gross et al.
patent: 2005/0143452 (2005-06-01), Gross et al.
patent: 2005/0261347 (2005-11-01), Gross et al.
patent: 2006/0089405 (2006-04-01), Zhou et al.
patent: 2006/0111438 (2006-05-01), Gontcharov et al.
patent: 2006/0241176 (2006-10-01), Stack et al.
patent: 2006/0246551 (2006-11-01), Stack et al.
patent: 2006/0247276 (2006-11-01), Gross et al.
patent: 2006/0251172 (2006-11-01), Zhou et al.
patent: 2006/0252825 (2006-11-01), Tadyson et al.
patent: 2006/0258639 (2006-11-01), Logue et al.
patent: 2006/0258711 (2006-11-01), Rosenzweig-Lipson
patent: 2006/0258712 (2006-11-01), Jacobson
patent: 2006/0258713 (2006-11-01), Rosenzweig-Lipson
patent: 2006/0258714 (2006-11-01), Heffernan et al.
patent: 2006/0258739 (2006-11-01), Ai et al.
patent: 2007/0032515 (2007-02-01), Anand et al.
patent: 2007/0225334 (2007-09-01), Rosenzweig-Lipson
patent: 19909760 (1999-10-01), None
patent: 06316563 (1994-11-01), None
patent: WO-96/15099 (1996-05-01), None
patent: WO-96/15100 (1996-05-01), None
patent: WO-00/76990 (2000-12-01), None
patent: WO-2004/089410 (2004-10-01), None
patent: WO-2005/073210 (2005-08-01), None
patent: WO-2005/123681 (2005-12-01), None
patent: WO-2006/000902 (2006-01-01), None
Apiquian, R., et al., Amoxapine as an Atypical Antipsychotic: A Comparative Study Vs Risperidone, Neuropsychopharmacology, 30, 2236-2244 (2005).
U.S. Appl. No. 11/787,929, Yu et al.
U.S. Appl. No. 11/787,860, Gontcharov et al.
U.S. Appl. No. 11/787,663, Mirmehrabi et al.
Di Matteo, et al., “Selective blockade of serotonin 2C/2B receptors enhances dopamine release in the rat nucleus accumbens”,Neuropharmacology, 37: 265-272, 1998.
Office Action mailed Oct. 17, 2007 in U.S. Appl. No. 10/970,103 filed Oct. 21, 2004.
Office Action mailed Aug. 27, 2007 in U.S. Appl. No. 10/970,714 filed Oct. 21, 2004.
Office Action mailed Sep. 21, 2007 in U.S. Appl. No. 11/113,170 filed Apr. 22, 2005.
Office Action mailed Sep. 25, 2007 in U.S. Appl. No. 11/409,479 filed Apr. 21, 2006.
Office Action mailed Sep. 28, 2007 in U.S. Appl. No. 11/408,319 filed Apr. 21, 2006.
Office Action mailed Oct. 22, 2007 in U.S. Appl. No. 11/409,303 filed Apr. 21, 2006.
Office Action mailed Sep. 19, 2007 in U.S. Appl. No. 11/408,879 filed Apr. 21, 2006.
Office Action mailed Oct. 18, 2007 in U.S. Appl. No. 11/408,909 filed Apr. 21, 2006.
Notice of Allowance mailed Oct. 17, 2007 in U.S. Appl. No. 11/409,467 filed Apr. 21, 2006.
Di Matteo, et al., “SB 242 084, a selective serotonin 2C receptor antagonist, increases dopaminergic transmissions in the mesolibic system”,Neuropharmacology, 38: 1195-1205, 1999.
International Search Report, PCT/US2006/015191.
Jandura Janet
Rosenzweig-Lipson Sharon
Choate Hall & Stewart LLP
Leeser Erich A
Robidoux Andrea L. C.
Wilson James O.
Wyeth
LandOfFree
Therapeutic combinations for the treatment or prevention of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic combinations for the treatment or prevention of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic combinations for the treatment or prevention of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2812002